The emerging role of esketamine for chronic pain
Since the FDA approved esketamine (Spravato) for treatment-resistant depression and depressive symptoms in adults with MDD who had acute suicidal ideation in 2019, new information is emerging of it’s effect in patients with comorbid chronic pain and depression. At the annual American Psychiatric Association (APA) 2024 conference, a case report of sustained improvement of both pain […]
